Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease.

ABSTRACT:

Background

Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis. Additional S1PR modulators are being tested in clinical development programmes for both ulcerative colitis and Crohn's disease.

Aim

To provide an overview of advances in understanding S1PRs biology and summarise preclinical and clinical investigations of S1P receptor modulators in chronic inflammatory disease with special emphasis on inflammatory bowel diseases (IBD).

Methods

We performed a narrative review using PubMed and ClinicalTrials.gov.

Results

Through S1PRs, S1P regulates multiple cellular processes, including prolifera

SUBMITTER: Wang J 

PROVIDER: S-EPMC8766911 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature